Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer

Camrelizumab is a novel programmed cell death protein 1 (PD-1) inhibitor developed in China that exhibits good efficacy in several advanced cancer types, including non-small cell lung cancer (NSCLC); however, its utility as a neoadjuvant regimen in NSCLC remains unclear. Thus, the present study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xinlei, Shi, Xueliang, Luo, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178701/
https://www.ncbi.nlm.nih.gov/pubmed/35720491
http://dx.doi.org/10.3892/ol.2022.13336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178701/
https://www.ncbi.nlm.nih.gov/pubmed/35720491
http://dx.doi.org/10.3892/ol.2022.13336

Ejemplares similares